Fenbendazole, Ivermectin, and Mebendazole in Cancer: A 750+ Case Anecdotal Signal Analysis and Strategic Evidence Review (2026)
- Corrected the Hulscher et al. cohort size (197 enrolled patients, not 21) and added the journal's formal Expression of Concern plus a conflict-of-interest disclosure.
- Added the two legitimate, ASCO-tracked interventional trials of ivermectin in oncology, including ICONIC (NCT07487805).
- Added a positive mebendazole–colorectal-cancer RCT.
- Added ASCO's May 2026 Clinical Notice recommending against ivermectin and fenbendazole for cancer treatment outside of clinical trials.
- New Regulatory & Safety Update section, new FAQ section, and an updated Evidence Verdict table with E0–E5 tiering.
Fenbendazole, ivermectin, and mebendazole are antiparasitic drugs being explored off-label for cancer based on preclinical mechanisms and a large body of patient-reported anecdotes. Mebendazole has the longest human trial history of the three, with mixed results — one positive randomized trial in colorectal cancer and one negative randomized trial in glioblastoma. These agents should only be considered under direct physician supervision, alongside — never in place of — standard oncology care.
Abstract
Background: Cancer remains the second leading cause of death globally. Advanced-stage disease carries poor prognosis, and a significant proportion of patients either fail conventional therapy or seek adjunctive options. Over the past decade, the repurposed antiparasitic agents fenbendazole, ivermectin, and mebendazole have attracted increasing attention for potential anti-neoplastic activity based on preclinical and emerging clinical data — attention that intensified through 2026 alongside growing regulatory scrutiny.
Objective: To synthesise (1) a systematic case-series compilation of 760+ patient-reported outcomes across 31 cancer subtypes involving antiparasitic repurposed drugs; (2) the current professional and regulatory guidance on these agents, including ASCO's May 2026 Clinical Notice; and (3) a practical guide to AI-assisted personalisation of integrative oncology protocols.
Methods: Narrative review, systematic case-series aggregation from peer-reviewed publications, preprint servers, patient communities and physician-reported accounts, cross-checked in August 2026 against current professional-society guidance, clinical trial registries, and post-publication editorial actions. Evidence quality is stratified by conventional hierarchy (RCT, prospective cohort, case series, case report, preclinical) and mapped to a unified E0–E5 evidence tier used throughout this site.
Results: The case-series dataset encompasses 760+ cases across brain (129), prostate (128), breast (126), colorectal (82), lung (46), pancreatic (46), lymphoma (25) and 24 additional cancer subtypes. Reported outcomes include complete response (CR), partial response (PR) and stable disease (SD) in patients with stage III–IV disease, including many who had failed prior standard-of-care therapies. Separately, a 2026 single-institution chart review found 182 self-reported fenbendazole users among 297,223 visits at one major U.S. cancer center. No serious drug-related fatalities were identified in the compiled anecdotal reports.
Conclusions: These real-world observations remain observational and hypothesis-generating. The largest human dataset for the ivermectin–mebendazole combination (Hulscher et al. 2026, n=197) is now under a formal Expression of Concern from its publishing journal and carries an unresolved conflict of interest, and should not be treated as confirmatory. Prospective RCTs remain urgently needed.
Keywords: fenbendazole; ivermectin; mebendazole; cancer; repurposed drugs; metabolic oncology; ASCO clinical notice; Warburg effect; tumor microenvironment; integrative oncology; AI personalisation
Table of Contents
- Introduction: From Viral Claims to Evidence-Based Protocols
- Case Series: 760+ Real-World Outcomes Across 31 Cancer Types
- Mechanisms of Action: Why Antiparasitics May Affect Cancer
- Regulatory & Safety Update (2026): What ASCO and the FDA Say
- Cancer Metabolism: Beyond the Warburg Effect
- Diet, Fasting & Metabolic Therapies: What the Evidence Shows
- The Microbiome Revolution in Oncology
- Immunometabolism, Checkpoint Inhibitors & the Repurposed-Drug Trial Landscape
- AI-Personalisation Guide: Using Claude, ChatGPT, Gemini & Perplexity
- Evidence Verdict Table: What Science Supports vs. Does Not
- AI Model Commentary on This Framework
- Discussion
- Conclusion
- Frequently Asked Questions
- References
1. Introduction: From Viral Claims to Evidence-Based Protocols
The online cancer information landscape in 2026 is polarised between two extremes: conventional oncology — characterised by high evidentiary standards, often significant toxicity, and escalating cost — and alternative narratives that offer high hope but frequently low-quality or misrepresented evidence. The future of cancer care lies in neither extreme.
The future is integrative, systems-based oncology — combining tumour biology, metabolic control, immune optimisation, microbiome modulation, and precision targeting. This is the conceptual foundation of the Metabolic Cancer Protocol 2026. But 2026 has also been the year this specific corner of integrative oncology came under its sharpest formal scrutiny yet: in May, the American Society of Clinical Oncology (ASCO) — the largest professional body of oncologists in the United States — issued a Clinical Notice explicitly cautioning against using ivermectin or fenbendazole to treat cancer outside a registered trial, and in June the journal that published the largest human study of the ivermectin-mebendazole combination took the unusual step of issuing a formal Expression of Concern about that same study. Both developments are covered in full in Section 4 and woven throughout this update.
The question is not "conventional vs. alternative." The question is: which evidence-informed adjuncts, stacked intelligently with standard-of-care therapy, can improve outcomes for a specific patient with a specific tumour — and which claims have outrun the evidence that supports them?
This white paper addresses a knowledge gap by synthesising four bodies of work: (1) a growing corpus of 760+ real-world patient accounts involving antiparasitic drugs in cancer; (2) the current professional and regulatory guidance on these agents; (3) a mechanistically grounded 7-layer metabolic framework; and (4) a practical AI-personalisation guide enabling patients to interrogate their own medical records against this literature using leading AI models.
What began as a handful of isolated case reports — most notably Joe Tippens' widely shared stage 4 small-cell lung cancer account in 2019 — has evolved into a structured repository of more than 760 patient stories across 31 cancer subtypes. Each reflects resilience, lived experience, and a determination to explore every evidence-informed option available. These accounts are preserved here not to establish efficacy, but to make accessible what mainstream oncology journals rarely publish: the patient's voice — read alongside, not instead of, what the clinical evidence actually shows.
Like Alexander Fleming's 1929 penicillin paper — which received little attention for a decade before the 1940 Lancet publication changed medicine — groundbreaking observations in self-treating patients can precede formal validation by years. But the reverse is also true: a widely shared observational study can look compelling and still not hold up once independent scrutiny arrives, as this update's coverage of the Hulscher et al. controversy illustrates. Cochrane Review editor-in-chief Karla Soares-Weiser has noted that a lack of evidence of effectiveness is not the same as evidence of ineffectiveness — but that framing cuts both ways, and neither excuses skipping the scrutiny that separates a real signal from noise.
2. Case Series: 760+ Real-World Outcomes Across 31 Cancer Types
760+ total patient-reported and physician-reported cases compiled | 31 distinct cancer subtypes represented | 3 primary agents: Fenbendazole · Ivermectin · Mebendazole | ~70% of cases involve Stage III–IV disease | 0 serious drug-related fatalities identified in compiled anecdotal reports
Companion case-series pages across this network have continued to add reports since this dataset was last fully audited, with some trackers now approaching 763+ entries. The table below reflects the last complete network audit and should be read as a lower-bound anecdotal snapshot rather than a validated clinical registry — see each subtype's full sub-article for its current running count.
Case Distribution by Cancer Type
| Cancer Type | Cases (n) | Primary Agents Reported | Evidence Signal | Full Sub-Article |
|---|---|---|---|---|
| Brain / Glioblastoma (GBM) | 129 | Ivermectin, Mebendazole, Fenbendazole | Strong Signal | Read |
| Prostate Cancer | 128 | Fenbendazole, Ivermectin | Strong Signal | Read |
| Breast Cancer | 126 | Fenbendazole, Ivermectin, Mebendazole | Strong Signal | Read |
| Colorectal Cancer | 82 | Fenbendazole, Ivermectin | Strong Signal | Read |
| Lung Cancer | 46 | Fenbendazole, Ivermectin | Moderate Signal | Read |
| Pancreatic Cancer | 46 | Fenbendazole, Ivermectin, Mebendazole | Moderate Signal | Read |
| Lymphoma | 25 | Ivermectin, Mebendazole | Moderate Signal | Read |
| Bladder / Kidney (Urological) | 34 | Fenbendazole, Ivermectin | Moderate Signal | Read |
| Esophageal / Gastric Cancer | 23 | Fenbendazole | Moderate Signal | Read |
| Ovarian Cancer | 17 | Ivermectin, Fenbendazole | Moderate Signal | Read |
| Head & Neck Cancer | 17 | Fenbendazole, Ivermectin | Moderate Signal | Read |
| Skin Cancer / Melanoma | 16 | Ivermectin (topical), Fenbendazole | Moderate Signal | Read |
| Leukemia | 10 | Ivermectin, Mebendazole | Early Signal | Read |
| Liver / Bile Duct (Hepatobiliary) | 9 | Fenbendazole, Ivermectin | Early Signal | See main article |
| Multiple Myeloma | 7 | Mebendazole, Fenbendazole | Early Signal | See main article |
| Sarcoma | 7 | Fenbendazole | Early Signal | See main article |
| Uterine / Endometrial & Cervical Cancer | 7+11+6 | Ivermectin, Fenbendazole | Early Signal | Read |
| Thyroid Cancer | 4 | Ivermectin, Mebendazole | Early Signal | Read |
| Other Subtypes (PEComa, Thymus, Testicular, MDS, etc.) | ~15 | Various | Limited Data | See main article |
Beyond self-published case reports, a chart review presented at the 2026 ASCO Gastrointestinal Cancers Symposium found 182 self-reported fenbendazole users among 297,223 patient visits at a single major U.S. cancer center, using at least 138 different self-devised dosing schedules [65]. This is a useful independent signal that off-label use is real and widespread — and a reminder of how unstandardized and physician-invisible the dosing patterns often are in practice.
These case accounts are observational. Complete responses (CR/NED) in Stage IV cancer after prior chemotherapy failure are rare events in conventional oncology, making even small clusters of reported complete responses noteworthy as hypothesis-generating signals. They do not constitute proof of efficacy and should not replace standard-of-care oncology. Confounding factors, publication bias and survivorship bias are acknowledged limitations, and ASCO's May 2026 Clinical Notice explicitly cautions that anecdotal reports of this kind should not guide treatment decisions (see Section 4).
3. Mechanisms of Action: Why Antiparasitics May Affect Cancer
Fenbendazole, mebendazole and ivermectin were developed as antiparasitic agents but share molecular targets that intersect with cancer biology. The following summarises proposed mechanisms with supporting preclinical evidence:
| Drug | Primary Cancer Mechanism | Secondary Mechanisms | Evidence Base |
|---|---|---|---|
| Fenbendazole | Microtubule polymerisation disruption (β-tubulin binding), glucose uptake inhibition (GLUT transporters), p53 upregulation, apoptosis induction | Wnt/β-catenin suppression; VEGF inhibition; CDK4/6 downregulation; cancer stem cell (CD44+/CD24−) targeting | Preclinical + Case Series |
| Mebendazole | Microtubule disruption, anti-angiogenesis (VEGFR2 inhibition), KRAS/BRAF pathway modulation | Pro-apoptotic BCL-2 modulation; MDR reversal; synergy with docetaxel (prostate models) | Preclinical + Phase I/II RCTs (mixed results — see Section 8) |
| Ivermectin | P-glycoprotein (MDR1/ABCB1) inhibition, PAK1 kinase suppression, chloride channel activation inducing apoptosis | WNT-TCF suppression; immunogenic cell death; checkpoint-inhibitor synergy in preclinical breast models | Preclinical + Early-Phase Trials + Contested Observational Cohort |
Predictive Biomarkers for Antiparasitic Response
Not all tumours are equally likely to respond to these agents. Emerging evidence identifies the following biomarkers as potentially predictive:
| Biomarker | Drug Relevance | Predicted Effect |
|---|---|---|
| TUBB3 (β-III tubulin) overexpression | Fenbendazole, Mebendazole | Reduced sensitivity (resistance) |
| ABCB1 / MDR1 overexpression | Ivermectin (inhibits MDR1) | Ivermectin may overcome resistance |
| CD44+/CD24− (cancer stem cell fraction) | Fenbendazole | Potential preferential targeting of CSC subpopulation |
| pSTAT3 activation | Ivermectin, Mebendazole | Higher STAT3 → greater potential response |
| TP53 mutation status | Fenbendazole | Wild-type p53 tumours may respond better to p53-upregulating agents |
2026 Preclinical Additions: Related Benzimidazoles
Two 2026 laboratory studies extend this mechanistic picture but remain preclinical only. A July 2026 study from Charles University found that flubendazole — a close chemical relative of mebendazole — combined with temozolomide reduced glioblastoma cell proliferation and activated apoptosis pathways across three GBM cell lines. Separately, a June 2026 study from Rome reported that mebendazole significantly inhibited cell growth and migration in two pediatric low-grade glioma cell lines, and a companion June 2026 paper in Cell Reports Medicine found that mebendazole, incorporated into a broader metabolically targeted strategy, reduced tumour progression and invasion in animal models of pediatric high-grade glioma. None of these findings have yet been tested in human trials.
4. Regulatory & Safety Update (2026): What ASCO and the FDA Say
This section is new to the August 2026 update and is, in the editorial team's view, the single most important addition to this white paper.
The ASCO Clinical Notice (May 2026)
In May 2026, ASCO published a formal Clinical Notice addressing ivermectin and fenbendazole in cancer directly, prompted by a surge in patients self-medicating with these agents after exposure to social media testimonials. Its core conclusions:
- There is no robust, peer-reviewed clinical evidence that ivermectin or fenbendazole is safe or effective for treating any human malignancy.
- ASCO strongly cautions that neither drug should be used to treat cancer, or as an adjunct to established cancer therapy, outside the regulatory safeguards of a well-designed clinical trial.
- The combination of unproven benefit and documented potential for toxicity and drug interaction "presents an unacceptable risk to patients" [58].
- Fenbendazole holds no FDA or EMA approval for any human indication; ivermectin is FDA-approved only for specific parasitic infections, at doses well below those described in online cancer regimens.
Notably, ASCO's notice names ivermectin and fenbendazole specifically. Mebendazole — which has a longer, if mixed, human randomised-trial record (see Section 8) — is not named in the same notice, an important nuance for patients and clinicians weighing these three agents differently.
However, Dr. Paul Marik argues in his 2026 Substack essay that relying primarily on the absence of large randomized controlled trials can provide an incomplete picture of the evidence surrounding repurposed drugs. In his view, preclinical research, mechanistic studies, pharmacologic data, observational clinical experience, and emerging real-world evidence should also be considered when assessing whether these agents warrant further investigation.
This perspective does not establish clinical efficacy, but it supports the argument that the evidence base should be evaluated across multiple levels of evidence rather than through randomized trials alone.
The Clinical Trial Landscape ASCO Points To
As of the notice, ASCO identified two legitimate interventional trials studying ivermectin in oncology: a Phase I/II trial combining ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer, with preliminary data from the first nine enrolled patients presented at the 2025 ASCO Annual Meeting [61]; and ICONIC (NCT07487805), a randomized Phase II trial comparing different ivermectin doses alongside immune-checkpoint inhibitors in 80 patients with solid tumours, expected to begin enrolment around July 2026 with results not anticipated before late 2027 [62]. No comparable interventional trial of fenbendazole in human cancer currently exists.
Documented Safety Concerns
Beyond the absence of efficacy evidence, regulators and clinicians have flagged specific, documented risks: high-dose or prolonged fenbendazole exposure has been associated with bone marrow suppression, which can impair infection-fighting and clotting; hepatotoxicity (elevated liver enzymes) has been observed with high-dose mebendazole in trial settings [22]; and because most self-administered fenbendazole is sourced from veterinary formulations, purity and dosing consistency are not guaranteed the way they are for pharmaceutical-grade, prescription products. Ivermectin at the doses described in some online cancer protocols exceeds the range studied for its approved parasitic indications.
ASCO's guidance to oncology teams — and good general advice for patients considering any of these agents — centers on three principles: be proactive and ask directly about supplement and repurposed-drug use rather than waiting for patients to volunteer it; approach the conversation with empathy rather than judgment, since patients are often overwhelmed and influenced by hopeful social media narratives; and maintain the therapeutic relationship so patients keep sharing what they're actually doing, even when it involves agents their oncologist would not recommend [58,66]. If you are considering any of these drugs, the single most protective step is full transparency with your oncology team before you start — not after.
5. Cancer Metabolism: Beyond the Warburg Effect
One of the most cited frameworks in integrative oncology is the Warburg effect: the observation that cancer cells preferentially utilise aerobic glycolysis even in oxygen-rich conditions [1,2]. Modern research confirms that metabolic reprogramming is a core hallmark of cancer [3,4]. However, the clinical reality is substantially more complex.
Cancer metabolism encompasses glucose, glutamine, lipid and one-carbon metabolism — all supporting rapid proliferation, biomass synthesis and redox balance [3,5]. Crucially, cancer cells demonstrate metabolic plasticity: the ability to switch between glycolysis, oxidative phosphorylation (OXPHOS) and fatty acid metabolism in response to nutrient availability, therapeutic pressure and microenvironmental conditions [6–9].
Single metabolic interventions (e.g. ketogenic diet alone, fasting alone) are unlikely to be curative because cancer cells can switch fuel sources. The strategic implication: multi-modal metabolic stacking is required to close multiple metabolic "escape routes" simultaneously.
Immunometabolism: Where Metabolism Meets Immunity
A paradigm-shifting development in oncology is the field of immunometabolism [10,11]. Tumour metabolism actively suppresses immune function: lactate accumulation in the tumour microenvironment inhibits T-cell activity [14]; nutrient competition in the TME weakens anti-tumour immune responses [39,40]; and hypoxia-inducible factor (HIF-1α) upregulation diverts immune cells toward pro-tumour phenotypes. This explains why some patients fail immunotherapy while others achieve durable complete responses.
The Tumour Microenvironment: The Hidden Battlefield
The tumour microenvironment (TME) encompasses immune cells, vasculature, fibroblasts, metabolites and extracellular matrix components. Studies demonstrate that this ecosystem promotes tumour growth, suppresses anti-tumour immunity and drives metastasis [15,16]. Repurposed drugs — particularly ivermectin — are hypothesised to partially remodel the TME by inducing immunogenic cell death and restoring T-cell infiltration, though as Section 8 details, the strongest human dataset for this claim is currently contested.
6. Diet, Fasting & Metabolic Therapies: What the Evidence Shows
Dietary intervention is among the most actionable and lowest-risk adjuncts available to cancer patients. The evidence base as of 2026 supports the following hierarchy:
| Intervention | Evidence Quality | Key Finding (2024–2026) | Practical Role |
|---|---|---|---|
| Eliminate ultra-processed foods (UPF) | Strong | 2026 AACR study: UPF linked to reduced cancer survival. 2024 BMJ umbrella review (n=9.8M): UPF associated with 32 adverse health parameters. | Priority #1: foundational |
| Reduce dietary sugar | Strong | BMJ 2023 umbrella review (8,000+ studies): limiting dietary sugar reduces cancer risk and metabolic dysfunction. | Priority #1: foundational |
| Weight / insulin resistance management | Strong | Nature Communications 2026: insulin resistance linked to 25% higher risk across 12 cancer types; uterine cancer risk elevated 134%. | Priority #1: foundational |
| Mediterranean diet pattern | Strong | Harvard 2022: reduces stroke, heart disease, and certain cancers via anti-inflammatory mechanisms. | Long-term dietary framework |
| Ketogenic diet (KD) | Moderate | Alters tumour metabolism; may lower insulin/IGF-1 signalling. Nature 2025 review: KD modulates tumour-stroma macronutrient ecosystem. | Adjunctive; cancer-type specific |
| Intermittent fasting / caloric restriction | Moderate | Improves metabolic health markers; may enhance chemotherapy efficacy window. Caution: chronic extreme fasting can compromise immune surveillance. | Adjunctive; supervised use |
| Eliminate food preservatives | Moderate | BMJ 2026 (NutriNet-Santé cohort): higher preservative intake associated with increased overall and breast cancer incidence. | Preventive and adjunctive |
Strategies that lower insulin and IGF-1 signalling, improve the leptin-to-adiponectin balance, increase β-hydroxybutyrate production, reduce inflammatory cytokines, restrict methionine or serine, and optimise the timing of nutrient intake may collectively create a systemic metabolic "headwind" against cancer progression while enhancing immune surveillance. Small daily choices, consistently applied over years, may matter more than any single intervention.
7. The Microbiome Revolution in Oncology
Among the most clinically significant scientific advances of the past decade is the discovery that gut microbiome composition profoundly influences cancer outcomes. In a landmark series of 2018 Science papers, three independent research groups demonstrated that gut bacteria influence patient response to PD-1-based immunotherapy [17–20]. Microbiome composition affects survival outcomes [21], and may explain why two patients with histologically identical tumours can respond entirely differently to the same treatment.
Practical implications for the Metabolic Cancer Protocol: high-fibre dietary patterns, probiotic supplementation, avoidance of unnecessary antibiotics, and faecal microbiota transplantation (FMT) are all under investigation as strategies to optimise microbiome composition prior to immunotherapy.
8. Immunometabolism, Checkpoint Inhibitors & the Repurposed-Drug Trial Landscape
Checkpoint inhibitors (anti-PD-1, anti-CTLA-4) represent one of the most significant advances in oncology in decades [34,35]. Durable complete responses have been observed across multiple cancer types, including melanoma, lung cancer and microsatellite-instability-high (MSI-H) tumours. However, the majority of patients do not respond, and resistance is common. This section covers what current evidence actually shows about repurposed drugs in this space — including the corrections this update makes to how that evidence has previously been characterised on this site.
The Hulscher et al. 2026 Cohort — Corrected, With Essential Context
The Hulscher et al. cohort, published in Anticancer Research in June 2026 (following an April 2026 preprint), followed 197 cancer patients prescribed a compounded ivermectin–mebendazole capsule (25 mg ivermectin / 250 mg mebendazole) off-label through a U.S. telemedicine platform. Of these, 122 patients (61.9%) completed a 6-month follow-up survey, and among respondents, 84.4% self-reported cancer disappearance, tumour regression, or disease stabilization [59]. An earlier version of this article cited this cohort as n=21; the correct enrolled cohort size is 197, with 122 completing follow-up. This is the largest published real-world dataset on the ivermectin-mebendazole combination — but it comes with major, disclosed caveats.
Several of the study's authors, including senior author Peter A. McCullough, are affiliated with The Wellness Company, the telemedicine company that prescribes the compounded ivermectin-mebendazole product being studied — a direct financial interest readers should weigh alongside the results. Days after publication, the Editorial Board of Anticancer Research issued a formal Expression of Concern (June 9, 2026), citing unresolved questions about the verifiability, statistical reliability, and ethical oversight of the underlying dataset [60]. As of this update, the paper has not been retracted, but it should not be treated as settled evidence. All outcomes were self-reported by patients via survey, with no control group, no imaging confirmation required, and roughly 38% loss to follow-up — standard limitations of this type of observational data, which the authors themselves describe as hypothesis-generating rather than confirmatory.
Disclosure: OneDayMD / One Day Media maintains an independent affiliate relationship with The Wellness Company (referral code ONEDAYMD). This relationship does not influence the evidence grading applied in this article, and we have applied the same scrutiny to this study that we would apply to any other source.
Legitimate Interventional Trials
Two ASCO-tracked interventional trials are testing ivermectin in oncology as of this update: a Phase I/II trial combining ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer, with preliminary data on the first nine patients presented at the 2025 ASCO Annual Meeting [61]; and ICONIC (NCT07487805), a randomized Phase II trial comparing ivermectin doses alongside checkpoint inhibitors in 80 patients with solid tumours, expected to begin enrolment around July 2026, with results not anticipated before late 2027 [62].
Randomized Trial Evidence for Mebendazole Is Mixed
Unlike fenbendazole (zero human trials) and ivermectin (early-phase trials only), mebendazole has an actual randomized human trial record — and it cuts both ways. A 2022 double-blind, placebo-controlled trial in 40 patients with metastatic colorectal cancer (Hegazy et al., Life Sciences) found that adding mebendazole to bevacizumab/FOLFOX4 chemotherapy improved response rates as an adjunct [64]. Conversely, a randomized Phase II trial in recurrent glioblastoma (Patil et al., eClinicalMedicine 2022) testing mebendazole added to temozolomide or lomustine failed to meet its pre-specified 9-month overall survival benchmark of 55% — the temozolomide-mebendazole arm reached 36.6% and the lomustine-mebendazole arm reached 45% [63]. A subgroup with good performance status (ECOG 0–1) on the lomustine-mebendazole arm did reach 57.9% 9-month OS, suggesting patient selection may matter — but neither trial evaluated mebendazole as a standalone treatment, and neither should be read as proof that mebendazole "works" against cancer in general.
Older preclinical and small-trial data remain part of the picture: a 2021 NPJ Breast Cancer study demonstrated ivermectin synergy with checkpoint inhibitors in preclinical breast cancer models, driving immunogenic cell death and increasing tumour-infiltrating lymphocytes [A]; and a 2019 British Journal of Cancer study reported mebendazole-docetaxel combination activity in prostate cancer models [B]. GLP-1 receptor agonists (semaglutide, tirzepatide) were reported at ASCO 2025 to modestly reduce risk across 14 obesity-related cancer types in patients with diabetes — a separate but related thread underscoring the insulin-cancer link.
9. AI-Personalisation Guide: Using Claude, ChatGPT, Gemini & Perplexity to Personalise Your Cancer Protocol
No two cancers are the same. A breast cancer patient with HER2+ disease, BRCA1 mutation, MSI-H status and high tumour mutational burden (TMB) has a fundamentally different tumour biology from a triple-negative breast cancer patient with TUBB3 overexpression and MDR1 amplification. Generic protocols cannot account for this heterogeneity. AI tools can help bridge the gap between general frameworks like this one and your specific tumour profile — but only as decision-support tools, never as a replacement for your oncology team.
Step-by-Step Guide to AI-Assisted Protocol Personalisation
1. Gather Your Medical Documents. Collect all relevant records in digital format (PDF, JPG, or plain text): pathology/biopsy report; immunohistochemistry (IHC) report (ER/PR/HER2, PD-L1 TPS/CPS, etc.); genomic sequencing report (Foundation One CDx, Guardant360 ctDNA, or equivalent); PET/CT or MRI scan reports; blood panels (tumour markers, CBC, metabolic panel, HbA1c, vitamin D, CRP); current treatment plan; prior treatment history.
2. Choose Your AI Platform. Each major AI model has different strengths for this use case — see the comparison below.
3. Upload Documents & Set Context. Most AI platforms accept PDF and image uploads. Begin your session with a structured prompt describing your age, sex, cancer type and stage, pathology and genomic findings, current treatment, and ask the AI to map the components of the Metabolic Cancer Protocol 2026 that are most relevant to your specific biomarker profile, and to flag which components (like Layer 5) carry the most unresolved regulatory caution.
4. Interrogate the Case Series. Copy the relevant cancer-subtype section from the case series into your AI session and ask which reports most resemble your situation, what protocols those patients used, and what the key differences are from your own case.
5. Generate an Oncologist Discussion Guide. Ask the AI to produce a structured, evidence-referenced list of questions for your oncologist or integrative physician — including specific questions about drug interactions and about whether you might be eligible for a registered trial such as ICONIC.
6. Set Up Ongoing Monitoring Prompts. After each blood test, scan or treatment cycle, upload new results and ask the AI to compare with prior results, identify trends, and flag values that warrant discussion with your medical team.
AI Platform Comparison for Cancer Protocol Personalisation
Claude (Anthropic) — Best for document analysis and long reports. Claude is well suited to reading, synthesising and reasoning across long, complex medical documents — including multi-page pathology reports, genomic sequencing PDFs and journal articles in a single session. Use it to cross-reference multiple documents at once, request a structured oncologist discussion guide in a specific format, and maintain ongoing cancer-management context across sessions. Access at claude.ai. Always verify AI-generated medical analysis with your healthcare provider — Claude does not have access to your oncologist's clinical context.
ChatGPT (OpenAI) — Best for research deep-dives and drug-interaction checks. Strong for searching current literature, cross-referencing drug interactions, and analysing numerical blood-test trends from uploaded files. Access at chatgpt.com.
Gemini (Google) — Best for real-time literature and Google Scholar integration. Useful for identifying current clinical trials (including registered trials like ICONIC), recently published case reports, and emerging research on your specific cancer type. Access at gemini.google.com.
Perplexity AI — Best for quick, citation-backed evidence searches. Every response includes source links, making it easier to bring credible references to your oncologist; its academic focus mode restricts results to peer-reviewed literature. Access at perplexity.ai.
AI models are decision-support tools, not oncologists. They can hallucinate (generate plausible-sounding but incorrect information — including, as this update illustrates, getting a study's sample size wrong), may not have access to the most recent clinical data, and cannot examine you clinically. Always: (1) verify AI-generated drug dosing and interaction information with your pharmacist and oncologist; (2) never discontinue or modify conventional treatment based on AI advice alone; (3) bring AI-generated summaries to your medical team as a discussion starter, not a decision document; (4) use AI from reputable, well-resourced companies with clear privacy policies.
10. Evidence Verdict: What Science Supports vs. Does Not Support
Evidence Tier key (unified E0–E5 scale used across this site): E0 = no supporting data / theoretical only · E1 = preclinical (in vitro / animal) only · E2 = anecdotal / case reports / case series · E3 = observational or prospective cohort (uncontrolled) · E4 = randomized controlled trial(s), single or mixed results · E5 = consistent RCT evidence, meta-analysis, or professional-society consensus.
| Intervention / Claim | Verdict | Evidence Tier | Notes |
|---|---|---|---|
| Cancer metabolism is a core therapeutic target | ✅ Supported | E5 | Warburg effect is real; metabolic reprogramming is a hallmark of cancer |
| Gut microbiome influences immunotherapy response | ✅ Supported | E4–E5 | 2018 Science triple-paper landmark series; FMT trials ongoing |
| Eliminating ultra-processed food improves cancer outcomes | ✅ Supported | E4 | 2024 BMJ umbrella review (n=9.8M); 2026 AACR cancer survivor study |
| Insulin resistance is a cancer risk modifier | ✅ Supported | E4 | Nature Communications 2026: 25% higher risk across 12 cancers |
| Ketogenic diet as adjunct (not cure) | ◐ Adjunctive | E2–E3 | Metabolic plasticity limits mono-dietary approaches |
| ASCO recommends against ivermectin/fenbendazole outside a trial | ✅ Current professional guidance | E5 | May 2026 ASCO Clinical Notice [58] |
| Fenbendazole anticancer activity in humans | ◐ Preclinical promise only | E1–E2 | No human trials exist; biological plausibility only; 760+ case series |
| Ivermectin + mebendazole produces high self-reported benefit (Hulscher 2026) | ⚠️ Contested — under editorial scrutiny | E3 | Formal Expression of Concern issued; author COI disclosed; no control group [59,60] |
| Mebendazole improves response as chemo adjunct in metastatic colorectal cancer | ✅ Supported (single RCT) | E4 | Hegazy et al. 2022, n=40, double-blind placebo-controlled [64] |
| Mebendazole added to chemo improves survival in recurrent glioblastoma | ❌ Not supported (single RCT) | E4 | Patil et al. 2022 missed pre-specified primary endpoint [63] |
| Diet alone cures cancer | ❌ Not Supported | E0 | Metabolic plasticity allows tumour adaptation; no RCT demonstrates dietary cure |
| Universal cure from a single repurposed drug | ❌ Not Supported | E0 | Cancer is a systems disease; heterogeneity precludes universal solutions |
| Combination strategy (metabolic + immune + microbiome + targeted) | ✅ Supported | E4–E5 | No single pathway dominates; combination approaches are scientifically sound |
11. AI Model Commentary on This Framework
The reflections below are informal commentary generated by general-purpose AI systems when prompted to critique this framework. They are included for reader interest and transparency about how different AI models characterise the protocol — they are not a substitute for, and should not be read as, formal scientific peer review.
Grok (xAI): This is one of the more thoughtful, multi-layered integrative metabolic cancer frameworks available online in 2026. It avoids wild cure-all claims and tries to synthesise diet, drugs and lifestyle logically, with a 2026 pivot toward insulin/GLP-1 optimisation. The metabolic-terrain and dietary layers have the strongest backing; the repurposed-drug stack remains experimental and off-label, and its strongest supporting human study is now under a publisher's Expression of Concern — a fact any reader weighing this framework should register clearly.
ChatGPT (OpenAI): This protocol is best understood as a structured hypothesis and integrative framework — not a clinically validated treatment model. It is useful for research direction and for stimulating informed patient-oncologist dialogue. The 7-layer model is internally consistent and, in this update, appropriately foregrounds ASCO's May 2026 guidance and the controversy around its central observational study rather than burying it.
Gemini (Google): The 2026 protocol represents an evolution in integrative oncology, shifting focus toward metabolic flexibility and multi-modal stacking. The AI-personalisation guide remains valuable in democratising access to evidence synthesis. The framework correctly positions all interventions as adjunctive rather than curative, and this update's addition of a dedicated regulatory-and-safety section is a meaningful improvement in responsible framing.
Perplexity: The OneDayMD 7-Layer Metabolic Cancer Protocol remains a plausible, conceptually modern scheme that aligns metabolic oncology ideas with conventional treatment, but it is a discussion framework rather than a validated cancer-cure protocol. It is most useful for patients who already have standard oncology care in place, who use it as a discussion starter with their doctor, and who do not substitute any of these agents for chemotherapy, radiation, immunotherapy or surgery — a position now reinforced, not undermined, by ASCO's formal 2026 guidance.
12. Discussion
The findings compiled in this white paper present a coherent, if incomplete and now more contested, picture of antiparasitic repurposing as a proposed adjunctive strategy in oncology. Mechanistic preclinical data remain genuinely interesting; a 760+-account observational case series remains the largest open-access dataset of its kind; and a phase I/II ivermectin-checkpoint-inhibitor trial and the ICONIC trial represent real, if early, prospective clinical investigation. But 2026 also delivered two sobering developments that any responsible synthesis has to sit with: ASCO's formal recommendation against using ivermectin or fenbendazole outside a clinical trial, and the Expression of Concern attached to the largest human observational study of this drug combination, published by authors with an undisclosed-until-scrutinized financial stake in the product being studied.
The Metabolic Cancer Protocol 2026 still addresses a genuine unmet need: the structured integration of evidence-informed metabolic, immunological and microbiome-directed adjuncts alongside conventional cancer therapy. Layers 1, 2, 3, 4, 6 and 7 rest on progressively stronger footing than Layer 5, whose antiparasitic-drug component is precisely the piece ASCO singled out for caution. This is consistent with the evolving hallmarks-of-cancer framework [32,33], which recognizes metabolic reprogramming, tumour microenvironment remodelling and immune evasion as core dimensions of malignant transformation — without implying that every agent that plausibly touches those pathways is therefore a validated treatment.
The AI Personalisation Paradigm
The incorporation of AI-assisted personalisation still represents a meaningful shift in how patients can engage with complex oncology evidence. Stanford's Michael Snyder has articulated a version of the "N=1" precision-medicine vision — that individualized data can now inform specific recommendations at the level of a single patient — and that vision is increasingly achievable using commercially available AI tools, provided patients treat AI output as a starting point for their oncology team's judgment rather than a conclusion.
Limitations
This white paper has several important limitations. The case series data is subject to significant survivorship bias, publication bias and self-selection bias. Patients who experience adverse outcomes are less likely to share their stories publicly. Confounding factors including concurrent conventional therapy, nutritional status, performance status and tumour heterogeneity are rarely adequately characterised in patient-reported accounts. The biological plausibility of the proposed mechanisms does not, in itself, establish clinical efficacy in humans — and the Hulscher et al. cohort, this update's most significant correction, illustrates how quickly a widely shared observational result can attract formal editorial scrutiny.
The Path Forward
The most direct path to evidential clarity remains a well-designed, adequately powered prospective registry study or randomized trial — and 2026's events make that path more urgent, not less. Dr John Campbell's proposal for large national cohorts tracked over time with rigorous statistical analysis remains a practical, lower-cost complement to a traditional pharmaceutical RCT, provided it is designed with the kind of independent oversight and pre-registration that would have pre-empted this year's Expression of Concern.
13. Conclusion
Cancer is not a single disease but a family of diseases united by the hallmarks of uncontrolled growth, immune evasion and metabolic reprogramming. No single intervention — conventional or integrative — addresses all of these dimensions simultaneously. The Metabolic Cancer Protocol 2026 proposes a rational, 7-layer adjunctive framework that stacks evidence-informed interventions across metabolism, immunity, microbiome, nutrition, repurposed drugs and lifestyle — each targeting distinct but interconnected aspects of cancer biology, and each held to a different current standard of evidence.
The 760+ case series compiled across 31 cancer subtypes remains one of the largest open-access observational datasets on antiparasitic repurposing in oncology. But 2026 is also the year the field's own professional society said, in the clearest possible terms, that this evidence does not yet support using ivermectin or fenbendazole to treat cancer outside a clinical trial — and the year the most-cited human study of the ivermectin-mebendazole combination came under formal editorial scrutiny alongside an unresolved financial conflict of interest. Both facts belong in this article, front and center, alongside the hope that motivated the original case series.
The AI personalisation guide offered in this paper remains a practical bridge between the general framework and the individual patient. This is not a replacement for oncology care; it is an enhancement of informed patient agency — one that, used well, should make patients more likely to bring these exact questions and controversies to their oncologist, not less.
If you or a loved one are facing cancer, particularly advanced-stage disease: do not lose hope, and do not lose your oncologist as your primary partner. This framework exists to complement, inform and enrich that partnership — not to replace it, and not to substitute a patient testimonial or a contested observational study for the judgment of the physician who knows your case.
"When you've tried everything, sometimes it's the unexpected that brings the miracle." — OneDayMD
"N=1 is the future." — Michael Snyder, Stanford Medicine
This white paper is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or a recommended treatment protocol. The content has not been reviewed by regulatory authorities. Fenbendazole, ivermectin and mebendazole are discussed here in the off-label context described; their efficacy and safety in cancer have not been established through randomised controlled trials, and as of May 2026 ASCO has formally recommended against using ivermectin or fenbendazole to treat cancer outside a registered clinical trial. Always consult a qualified oncologist, physician and pharmacist before making any changes to your cancer treatment.
Affiliate & Conflict-of-Interest Disclosure: The OneDayMD Editorial Team may receive affiliate commissions from links in this article, including from The Wellness Company (referral code ONEDAYMD) and Amazon Associates. This does not influence editorial content or evidence grading. Where a cited study's authors share a financial relationship with The Wellness Company — as with the Hulscher et al. 2026 cohort discussed in Section 8 — that relationship is disclosed directly in the text. No payment is required to access this information.
14. Frequently Asked Questions
Do fenbendazole, ivermectin, or mebendazole cure cancer?
No. No completed randomized controlled trial has shown that any of the three cures cancer in humans. Laboratory and animal studies show plausible anticancer mechanisms, a large body of patient-reported anecdotes exists, and one small randomized trial found mebendazole improved response rates as an add-on to chemotherapy in metastatic colorectal cancer — but this is not the same as a proven standalone cure, and a separate randomized trial found mebendazole did not improve survival when added to chemotherapy in recurrent glioblastoma.
What does ASCO say about using these drugs for cancer?
In a May 2026 Clinical Notice, ASCO stated there is no robust, peer-reviewed clinical evidence that ivermectin or fenbendazole is safe or effective for treating any human malignancy, and strongly cautioned against using either outside the safeguards of a registered clinical trial, citing the risk of toxicity and harmful drug interactions.
Is the Hulscher et al. ivermectin-mebendazole study reliable?
It should be treated with real caution. The study reported that 84.4% of the 122 patients who completed 6-month follow-up (out of 197 enrolled) self-reported cancer disappearance, regression, or stabilization. However, several authors are affiliated with The Wellness Company, which markets the product studied, and the publishing journal issued a formal Expression of Concern about the dataset's verifiability and statistical reliability shortly after publication. The results are hypothesis-generating, not confirmatory.
Are there any legitimate clinical trials studying ivermectin for cancer?
Yes, two. A Phase I/II trial is combining ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer. ICONIC (NCT07487805) is a randomized Phase II trial comparing ivermectin doses alongside checkpoint inhibitors in 80 patients with solid tumours, expected to begin enrolling around July 2026, with results not expected before late 2027.
Is fenbendazole approved by the FDA for any human use?
No. Fenbendazole is approved only as a veterinary anthelmintic (marketed as Panacur C or Safe-Guard) and has no FDA or EMA approval for any human indication, including cancer. High-dose or prolonged use has been associated with bone marrow suppression.
What is the Joe Tippens Protocol?
It refers to the off-label combination of fenbendazole with supplements popularized by Joe Tippens, who credits it with contributing to his remission from metastatic small-cell lung cancer diagnosed in 2017. As of 2026 he reports remaining cancer-free while continuing a maintenance version of the protocol. His account is one widely cited case report among the 760+ compiled here — anecdotal, not clinical trial evidence.
What are the safety risks of self-medicating with these drugs for cancer?
Documented concerns include bone marrow suppression and liver toxicity with high-dose or prolonged fenbendazole/mebendazole use, inconsistent purity in veterinary-sourced formulations, and drug-drug interactions with active chemotherapy or immunotherapy regimens. Ivermectin doses described in some online protocols exceed the range studied for its FDA-approved parasitic indications.
Should I tell my oncologist if I'm using these drugs?
Yes, always, before starting rather than after. ASCO specifically encourages oncology teams to ask proactively about supplement and repurposed-drug use, and to respond with empathy rather than judgment. Full transparency is the single most protective step you can take, since it allows your care team to screen for interactions and monitor for toxicity.
References
[1] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.
[2] Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211–218.
[3] Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47.
[4] Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308.
[5] DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.
[6] Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.
[7] Martinez-Outschoorn UE, et al. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11–31.
[8] Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 2020;32(3):341–352.
[9] Ashton TM, et al. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482–2490.
[10] Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169(4):570–586.
[11] O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism. Nat Rev Immunol. 2016;16(9):553–565.
[14] Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559–563.
[15] Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566.
[16] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.
[17] Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy. Science. 2018;359(6371):91–97.
[18] Gopalakrishnan V, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy. Science. 2018;359(6371):97–103.
[19] Zitvogel L, et al. The microbiome in cancer immunotherapy. Nat Rev Immunol. 2018;18(8):521–533.
[20] Matson V, et al. The commensal microbiome is associated with anti-PD-1 efficacy. Science. 2018;359(6371):104–108.
[21] Helmink BA, et al. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377–388.
[22] Bota DA, et al. Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. Neurooncol Adv. 2021;3:vdaa154.
[32] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
[33] Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.
[34] Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy. Science. 2015;348(6230):56–61.
[35] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355.
[39] Chang CH, et al. Metabolic competition in the tumor microenvironment. Cell. 2015;162(6):1229–1241.
[40] Ho PC, et al. Phosphoenolpyruvate is a metabolic checkpoint of T cell function. Cell. 2015;162(6):1217–1228.
[51] Hulscher N, et al. Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Zenodo Preprint. April 2026. Superseded by peer-reviewed publication [59]; see also Expression of Concern [60].
[52] Bonaccio M, et al. Ultra-processed food and mortality among long-term cancer survivors from the Moli-sani study. Cancer Epidemiol Biomarkers Prev. 2026.
[53] Hasenbohler A, et al. Intake of food additive preservatives and incidence of cancer: results from the NutriNet-Santé prospective cohort. BMJ. 2026.
[54] Lee S, et al. Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer. Nature Communications. 2026.
[55] Lane MM, et al. Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses. BMJ. 2024.
[56] Huang Y, et al. Dietary sugar consumption and health: umbrella review. BMJ. 2023.
[57] OneDayMD Editorial Team. Triple combination of Ivermectin, Mebendazole and Fenbendazole for Cancer: 16 Case Reports. OneDayMD Substack. 2026.
[58] American Society of Clinical Oncology. ASCO Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment, Outside of Clinical Trials. May 2026.
[59] Hulscher N, Victory K, Thorp JA, Pinsky D, Diaz-Villalobos A, Gillooly P, Coulson F, Annazone M, Radesi C, Brooks J, McCullough PA, Risch H. Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Anticancer Res. 2026;46(6):3243–3255. doi:10.21873/anticanres.18194.
[60] Editorial Board. Expression of Concern: Hulscher et al., Anticancer Res 2026;46(6):3243–3255. Anticancer Res. 2026;46(6):e3243. doi:10.21873/anticanres.18276.
[61] A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer. J Clin Oncol. 2025;43:16s(suppl; abstr e13146).
[62] Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC). ClinicalTrials.gov identifier NCT07487805.
[63] Patil VM, Menon N, Chatterjee A, Tonse R, Choudhari A, Mahajan A, Puranik AD, Epari S, Jadhav M, Pathak S, Peelay Z, Walavalkar R, Muthuluri HK, Krishna MR, Chandrasekharan A, Pande N, Gupta T, Banavali S, Jalali R. Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: a randomised open-label phase II trial. eClinicalMedicine. 2022. doi:10.1016/j.eclinm.2022.101449.
[64] Hegazy SK, et al. Mebendazole added to bevacizumab/FOLFOX4 in metastatic colorectal cancer: a randomized, double-blind, placebo-controlled trial. Life Sciences. 2022.
[65] Phan MV, Willis J, Hu ZI. A single institutional experience on patterns of ivermectin and fenbendazole use among patients with gastrointestinal cancers. J Clin Oncol. 2026;44(2_suppl):818.
[66] Gilligan T, Bohlke K, Alpert AB, et al. Patient-Clinician Communication: ASCO Guideline Update. J Clin Oncol. 2026;44(11):1040–1057.
[A] Juarez M, et al. Ivermectin and doxorubicin combination therapy activates microRNA Let-7 and induces cell death in PD-L1-positive breast cancer. NPJ Breast Cancer. 2021. doi:10.1038/s41523-021-00229-5.
[B] Bai R-Y, et al. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor growth in a model of prostate cancer. Br J Cancer. 2019. doi:10.1038/s41416-019-0681-5.
OneDayMD — Conventional medicine saves lives. Innovative and integrative approaches can extend and enhance them.
OneDayMD.com | Cancer.AestheticsAdvisor.com | Substack | About Us
© 2026 OneDayMD / One Day Media. All rights reserved. | Last Updated: August 19, 2026 | Version 4.0
This white paper is for educational purposes only and does not constitute medical advice. See full disclaimer above.
This manuscript has not completed formal peer review and should not be cited as established clinical evidence.
.png)
.png)
.png)
Comments
Post a Comment